People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Agtech / Foodtech, Biotech / Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Good Day Farm Arkansas, LLC | — | Agtech / Foodtech | Series C | $66.2M | $97.9M | 2020 |
| Good Day Farm Louisiana, LLC | — | Agtech / Foodtech | Series B | $54.0M | $265.8M | 2021 |
| NOLA PharmaHoldings, LLC | — | Biotech / Pharma | Series C | $48.1M | $448.1M | 2024 |
| Missouri Acquisition Co 5, LLC | — | Other | Series B | $20.0M | $195.5M | 2022 |
| Wellcana Plus, LLC | — | Other | Series B | $18.9M | $9.1M | 2021 |
| Missouri Vertical Investments LLC | — | Other | Series A | $18.1M | $27.0M | 2023 |
| MO-MMD Investment Company, LLC | — | Other | Series A | $12.3M | $119.6M | 2021 |
| Good Day Farm Mississippi, LLC | — | Agtech / Foodtech | Series A | $9.1M | $13.8M | 2020 |
| MAC5 Investment Company, LLC | — | Other | Pre-Seed | $200K | $1.8M | 2022 |
Alex Gray at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alex Gray on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Reid Dove | 7 | 10 |
| Peyton Bush | 3 | 5 |
| Stephen LaFrance | 3 | 4 |
| Eric Thornton | 3 | 3 |
| Mitchell Massey | 2 | 3 |
| Nate Steel | 2 | 2 |
| James Smith | 1 | 20 |
| William M Mounger, II | 1 | 6 |
| Stephen L. LaFrance, Jr. | 1 | 6 |
| Ryan Herget | 1 | 5 |
| Reid L. Dove | 1 | 5 |
| Todd Denton | 1 | 2 |
| Terry Fitch | 1 | 2 |
| Ray Boyer | 1 | 2 |
| William E. Walker, III | 1 | 1 |
| Kevin Wilcox | 1 | 1 |
| Mitchell L. Massey | 1 | 1 |
| Stephen LeFrance | 1 | 1 |
| Stephen LaFrance, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.